Preparing for the next infectious disease pandemic
Dr Owain Millington, Chief Executive Officer at ILC Therapeutics, explores some of the areas of unmet need in infectious disease, and where the search for pleiotropic, broad-spectrum antivirals could lead drug development.
Introduction
Whilst the Covid-19 pandemic caused a step change in global investment for infectious diseases, there remains significant unmet need for broad-spectrum antivirals that can address infection and prevent serious illness. Innovative therapies that demonstrate pleiotropy, with multiple mechanisms of action to target separate aspects of disease, would improve outcomes our pandemic preparedness; however, complex biology means the molecules with these attributes often come with serious side effects when used as therapies.
Recent progress
The years immediately following the pandemic have seen increased investment in infectious disease, with multiple notable exits taking place. Examples include Pfizer’s acquisition of ReViral, Biocure Technology’s reverse takeover agreement with Atriva Therapeutics, and AstraZeneca’s acquisition of Icosavax.
Perhaps the hottest infectious disease space in recent years outside of Covid-19 has been respiratory syncytial virus (RSV). Recent approvals of the first vaccines represented a landmark moment for a disease that has a severe burden on global health, with around 64 million people affected annually, with approximately 58,000 hospitalisations caused among children under five in the US. Annually1. In addition to its risk in infants, RSV is estimated to cause 8,200 in-hospital deaths in the US for those aged 60 and older, with RSV’s economic cost in this demographic estimated at $6.6bn annually2.
RSV poses a more severe burden than influenza, as older adults face more severe respiratory symptoms, higher comorbidities, and greater use of healthcare resources. No RSV-specific antiviral is currently approved for adults, and the current treatment focuses on supportive care. Ribavirin is commonly used to treat severe cases of RSV infection, however, it is not approved for RSV treatment in adults and is therefore used off-label in these cases. The overall lower one-year survival rate and higher readmission risks for RSV vs influenza make a strong case for the urgent development of novel approaches to RSV therapy.
Other areas of infectious disease that have seen significant activity in recent years include hepatitis B and hepatitis C, where there is unmet need for improved therapies, and biopharma are progressing novel candidates.
Understandably, there also has been a sharp increase in focus on pandemic preparedness, or viruses which are likely to increase in incidence in the coming years. Several viruses have been identified as priorities for global health to tackle in coming years, including Zika, Dengue and Chikungunya, particularly as climate change is projected to increase the ability of these disease to spread across the world.
Broad spectrum antivirals
One study recently found that the likelihood of experiencing a severe pandemic similar to Covid-19 during one’s lifetime stood at around 38%3.
In his 2022 book ‘How to Prevent the Next Pandemic’, Bill Gates said that to be better prepared for the next pandemic, we need to have therapeutics as well as the infrastructure to rapidly produce vaccines, stating that the most promising drugs in his view “are the ones known as pan-family and broad-spectrum therapies — either antibodies or drugs that can treat a wide range of viral infections, especially those that are likely to cause a pandemic.”
If we are collectively able to develop and stockpile antivirals that have activity across multiple viruses, that would be a huge step forward in our pandemic preparation. However, finding a therapy that works effectively across multiple viruses is particularly challenging.
Combination therapies
The ability to develop broad-spectrum drugs that can treat a wide range of infectious diseases, including key conditions that either have ‘pandemic potential’, or are currently a large burden on global health, or both, is limited by the fact that these indications often depend on combination therapies to treat the different aspects of a disease that cause illness.
For example, there are multiple aspects to a viral infection that cause illness. The presence of the virus within the tissues is the root cause, but the body’s own inflammatory response is often what causes the symptoms and severe illness, and the body’s own adaptive immune response plays a significant role in the severity of illness experienced.
Taking RSV as an example, its vaccines enhance the body’s adaptive immunity, providing protection upon exposure to the virus. However, the vaccines have thus far been targeted to the most vulnerable populations, with their coverage incomplete across the population, and even among those vaccinated the potential for severe illness remains. Monoclonal antibodies have shown success in reducing the viral levels in tissues, but they do not address the body’s inflammatory response.
Clinicians are now often using these targeted medicines in combination therapies to treat patients seriously unwell with infectious diseases, to help deal with both the infection, as well as the body’s own inflammatory responses. However, the combination approach has significant drawbacks – complications can arise from polypharmacy, and there is significant expense for biopharma to test these combinations, and for payers.
There is therefore enormous potential for novel multi-functional therapeutic candidates in infectious disease that can act on the different disease pathways – especially those that are able to reduce the body’s inflammatory response in the airways that causes illness.
Pleiotropic drugs
Finding drug candidates that display pleiotropy (regulating multiple disease pathways) is difficult due to inherently complex mechanisms of action and increased potential side effects. Optimising dosing with a wide-acting molecule to ensure a suitable effect on all targets whilst minimising adverse effects, as well as the pharmacokinetics and pharmacodynamics associated with addressing multiple targets, can also be complicated.
However, some naturally occurring pleiotropic molecules may have potential as a starting point for treating infectious diseases and beyond.
Interferons (IFNs) are the body’s first defence against pathogens, released by cells in response to viral infection. Their diverse mechanisms of action include the activation of immune cells, up-regulating antigen presentation, acting as a signalling bridge between the innate and adaptive immune system, and modulating multiple inflammatory pathways. Some specific IFN subtypes have been used in the clinic however their broad mechanisms of action can also cause severe side effects.
Other pleiotropic cytokines are in development, primarily in cancer, but may also have potential in other indications such as infectious disease. Innovative approaches are increasingly making these wide-acting molecules more viable as therapeutic options, such as targeted delivery systems, protein conjugates, or the selection and recombination of different natural protein domains to generate novel drug classes that retain or even enhance efficacy, and reduce side effects.
At ILC Therapeutics, we have developed a first-in-class technology platform whereby we can rationally select attributes from different natural interferons, producing a novel drug class: hybrid interferons. These chimeras are engineered to improve and build upon the efficacy and pleiotropy of natural interferons whilst also reducing their side effects. Our lead candidate, Alfacyte, is being developed to treat upper respiratory tract viral infections, and has shown activity against RSV, Covid-19, Zika and Dengue in preclinical tests. Alfacyte has been shown to reduce the levels of virus in tissues, regulate the inflammatory response, and also activate the innate immune system, whilst also reducing side effects in vivo and in vitro, which we believe indicates its potential as a broad-spectrum antiviral.
Whilst we have made progress in infectious disease, the ongoing health and economic burden of certain indications and the unfortunately likely prospect of another pandemic means that there is huge unmet need for broad-spectrum antivirals with pleiotropic mechanisms of action. Whilst some pleiotropic biologics have encountered issues when used as therapeutics, innovative approaches from biopharma show we are progressing towards a new generation of infectious disease medications.
From DDW Volume 26 – Issue 1, Winter 2024/25 Read the digital issue
References
- National Institute of Allergy and Infectious Diseases, Respiratory Syncytial Virus (RSV). https://www.niaid.nih.gov/diseases-conditions/respiratory-syncytial-virus-rsv
- Carrico et al. The Journal of Infectious Diseases, Volume 230, Issue 2, 15 August 2024, Pages e342–e352, https://academic.oup.com/jid/article/230/2/e342/7462192
- Proceedings of the National Academy of Sciences of the United States of America, Intensity and frequency of extreme novel epidemics. https://www.pnas.org/doi/10.1073/pnas.2105482118
About the author:
Dr Owain Millington has 20 years’ experience in immunology, having led an independent academic research group investigating immunity in the context of infectious and inflammatory diseases before moving into commercial biotechnology. He has strong experience in building and leading discovery and development teams, successfully identifying new candidates and delivering immunotherapy products into the clinic.
